Evaluating hERG channel activity requires a combination of high-throughput primary screens and precise secondary validation techniques. As detailed in the hERG Screening Market Analysis, technological developments in automated electrophysiology and fluorescence-based assays have significantly elevated the speed, accuracy, and cost-effectiveness of cardiac safety screening in drug discovery workflows.-
Primary High-Throughput Screening (HTS) Modalities
During early-stage discovery, pharmaceutical laboratories require high-capacity assays capable of screening thousands of compounds per day:
-
Fluorescence-Based Ion Flux and Membrane Potential Assays: Utilizing voltage-sensitive dyes or thallium flux indicators, these optical assays provide a cost-effective, high-throughput primary screen to identify potent hERG blockers in large chemical libraries.
-
Radioligand Binding Assays
